RESOURCES

Where research scientists come to find up to date resources on antibody discovery against challenging membrane protein targets.

Publications

500+ publications and patents

Featured Publications

Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point Screnci et al. 2022 iScience 25, 105665

Read More

Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape – Ku et al. 2021 Nature Communications 12, 469

Read More
Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications – Whitbeck et al. 2020 PLoS Neglected Tropical Diseases 14, e0008730

Read More

Additional publications by Integral Molecular

Case Studies

Featured Case Studies

AdAlta – Learn how Lipoparticles enabled the discovery of a CXCR4 clinical stage i-body
Read More
Novartis – Understanding mechanism of action: how a biparatopic CXCR2 nanobody inhibits with high potency and efficacy
Read More
Cabaletta Bio – Learn how the MPA was used to screen specificity of a novel T-cell therapeutic for a successful IND submission Read More
  • Claudin 6 – Isolation of highly specific MAbs against the tight junction protein Claudin 6 for solid tumors
  • GLUT4 – Discovery of state-specific antibodies against SLC2A4 (GLUT4), a complex 12-TM transporter, for diabetes
  • P2X7 – Agonist and antagonist MAbs targeting the P2X7 ion channel for autoimmune disorders
  • CB1 – Discovery of antagonist MAbs against the GPCR CB1 for treating NASH liver disease
  • GPCR – An agonist antibody targeting a challenging GPCR target
  • Ablynx – Learn how Lipoparticles rescued a CX3CR1 discovery campaign and enabled a clinical stage antibody
  • AdAlta – Learn how Lipoparticles enabled the discovery of a CXCR4 clinical stage i-body
  • Argenx – Learn how Lipoparticles were used to isolate antibodies with diverse epitopes against the GPCR glucagon receptor
  • Novartis – Understanding mechanism of action: how a biparatopic CXCR2 nanobody inhibits with high potency and efficacy
  • Merck – Epitope mapping of conformation specific RSV F antibodies
  • Covagen – Using epitope data to distinguish a novel bispecific HER2 antibody from existing therapeutics
  • Cabaletta Bio – Learn how the MPA was used to screen specificity of a novel T-cell therapeutic for a successful IND submission
  • Totient – Learn how Totient (now AbSci) used the MPA to deorphan intratumoral antibodies and identify potential oncology targets
  • AboundBio – Learn how the MPA was used to rapidly screen the specificity of a SARS-CoV-2 neutralizing antibody for therapeutics
  • FairJourney – See how FairJourney established that their antibodies against CXCR4 do not demonstrate off-target binding
  • Deorphaning – Learn how the MPA was used to deorphan panels of antibodies obtained through phenotypic screening
  • Takeda – Learn how dengue and Zika RVPs enabled clinical progression of Takeda’s Zika and dengue vaccines
  • University of Pittsburgh – Learn how researchers used SARS-CoV-2 RVPs to screen their nanobodies for virus-neutralizing activity, results published in Science
  • PPD– Learn how SARS-CoV-2 RVPs can be used for sera screening and immunogenicity assays.
  • Immunome – Learn how SARS-CoV-2 RVPs facilitated testing of a therapeutic antibody cocktail and enabled its progression to the clinic

Webinars

Featured Webinars

Conquering Undruggable Targets to Obtain Preclinical Antibodies


Watch Video
Specificity Testing of Antibody and CAR-T Cell Therapies for IND Using the Membrane Proteome Array

Watch Video
Innovative Research Tools to Combat Biological Threats


Watch Video